New Research Paper
Structural
The PARTNER 3 Bicuspid Registry for Transcatheter Aortic Valve Replacement in Low-Surgical-Risk Patients

https://doi.org/10.1016/j.jcin.2022.01.279Get rights and content
Under an Elsevier user license
open archive

Abstract

Objectives

The study compared 1-year outcomes between transcatheter aortic valve replacement (TAVR) patients with bicuspid aortic valve (BAV) morphology and clinically similar patients having tricuspid aortic valve (TAV) morphology.

Background

There are limited prospective data on TAVR using the SAPIEN 3 device in low-surgical-risk patients with severe, symptomatic aortic stenosis and bicuspid anatomy.

Methods

Low-risk, severe aortic stenosis patients with BAV were candidates for the PARTNER 3 (Placement of Aortic Transcatheter Valves 3) (P3) bicuspid registry or the P3 bicuspid continued access protocol. Patients treated in these registries were pooled and propensity score matched to TAV patients from the P3 randomized TAVR trial. Outcomes were compared between groups. The primary endpoint was the 1-year composite rate of death, stroke, and cardiovascular rehospitalization.

Results

Of 320 total submitted BAV patients, 169 (53%) were treated, and most were Sievers type 1. The remaining 151 patients were excluded caused by anatomic or clinical criteria. Propensity score matching with the P3 TAVR cohort (496 patients) yielded 148 pairs. There were no differences in baseline clinical characteristics; however, BAV patients had larger annuli and they experienced longer procedure duration. There was no difference in the primary endpoint between BAV and TAV (10.9% vs 10.2%; P = 0.80) or in the rates of the individual components (death: 0.7% vs 1.4%; P = 0.58; stroke: 2.1% vs 2.0%; P = 0.99; cardiovascular rehospitalization: 9.6% vs 9.5%; P = 0.96).

Conclusions

Among highly select bicuspid aortic stenosis low-surgical-risk patients without extensive raphe or subannular calcification, TAVR with the SAPIEN 3 valve demonstrated similar outcomes to a matched cohort of patients with tricuspid aortic stenosis.

Key Words

aortic stenosis
bicuspid
TAVR
transcatheter aortic valve replacement

Abbreviations and Acronyms

AVA
aortic valve area
BAV
bicuspid aortic valve
CAP
continued access protocol
KCCQ-OS
Kansas City Cardiomyopathy Questionnaire overall summary
KM
Kaplan-Meier
NYHA
New York Heart Association
P3
PARTNER 3 trial
PVR
paravalvular regurgitation
SAVR
surgical aortic valve replacement
STS PROM
The Society of Thoracic Surgeons Predicted Risk of Mortality
TAV
tricuspid aortic valve
TAVR
transcatheter aortic valve replacement

Cited by (0)

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.

Drs Williams and Jilaihawi contributed equally to this work.